Trial Profile
A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms TRANSFORM-UK
- 29 Sep 2021 Primary endpoint . (Pulmonary vascular resistance- dynes (cm-5) has not been met according to the results published in the European Respiratory Journal
- 29 Sep 2021 Results published in the European Respiratory Journal
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society